We have used different colon cancer samples and cell lines (SW480, SW620, SW48, KM12C and KM12SM) [29], [30], [31] to investigate the presence of SNPs or activating mutations in FGFR4 and to characterize its biological relevance as oncogene and therapeutic target in colorectal cancer. Here, FGFR4 is linked to colonic neoplasm.